TETRIS PHARMA LTD
Get an alert when TETRIS PHARMA LTD files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£305K
+724.3% vs 2024
Net assets
-£9.2M
+0.8% vs 2024
Employees
5
0% vs 2024
Profit before tax
£69K
+101.3% vs 2024
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Accounts not prepared on a going-concern basis
The Company ceased trading at the end of quarter three 2025. As at the balance sheet date, the directors have no intention to recommence trading. Accordingly, the directors have concluded that it is no longer appropriate to prepare the financial statements on a going concern basis. The financial statements have therefore been prepared on a non-going concern basis, and assets and liabilities are stated at amounts expected to be realised or settled in completing the orderly wind-down of the Company's affairs.
-
Going-concern uncertainty disclosed
-
Negative shareholders' funds
Net assets
2-year trend · vs Consumer Discretionary median
Accounts
2-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|
| Turnover | £2,761,000 | £1,303,000 | -52.8% | |
| Operating profit | -£5,162,000 | £740,000 | +114.3% | |
| Profit before tax | -£5,477,000 | £69,000 | +101.3% | |
| Net profit | -£5,477,000 | £69,000 | +101.3% | |
| Cash | £37,000 | £305,000 | +724.3% | |
| Total assets less current liabilities | — | — | — | |
| Net assets | -£9,233,000 | -£9,163,000 | +0.8% | |
| Equity | — | — | — | |
| Average employees | 5 | 5 | 0% | |
| Wages | £609,000 | £281,000 | -53.9% | |
| Directors' remuneration | £177,000 | £52,000 | -70.6% |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating margin | -187.0% | 56.8% | |
| Net margin | -198.4% | 5.3% | |
| Gearing (liabilities / total assets) | 499.5% | 2963.4% | |
| Current ratio | 1.24x | 0.03x | |
| Interest cover | -8.63x | 1.10x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Consolidated group
- Auditor
- PKF Littlejohn LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Not a going concern (break-up basis)
“The Company ceased trading at the end of quarter three 2025. As at the balance sheet date, the directors have no intention to recommence trading. Accordingly, the directors have concluded that it is no longer appropriate to prepare the financial statements on a going concern basis. The financial statements have therefore been prepared on a non-going concern basis, and assets and liabilities are stated at amounts expected to be realised or settled in completing the orderly wind-down of the Company's affairs.”
Group structure
- TETRIS PHARMA LTD · parent
- Tetris Pharma BV 100%
Significant events
- “On 9 January 2025, the management of Arecor Therapeutics plc decided to cease operations within the Group's subsidiary Tetris Pharma Limited during 2025. The cessation took place on 30 September 2025.”
- “On 8 May 2025, Arecor Therapeutics plc announced the sale of rights to certain non-Ogluo® products from its Tetris Pharma subsidiary to Aspire Pharma Limited. Under the terms of the agreement, Arecor received a cash payment of £0.5 million from Aspire in return for both the UK distribution rights to the products and the transfer of existing inventory.”
- “On 1 October 2025, the Marketing Authorisation for Ogluo® was returned to Xeris Pharmaceuticals.”
- “After the balance sheet date, the intercompany loan advanced by the Company to its subsidiary Tetris Pharma B.V. was capitalised in full. The loan balance was converted into equity in Tetris Pharma B.V., resulting in an increase in the subsidiary's share premium. As a result, the intercompany loan receivable previously recognised by the Company has been reclassified as an investment in subsidiary.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 7 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| ELLAM, David John | Director | 2025-03-24 | Oct 1963 | British |
| HOWELL, Sarah Jennifer, Dr. | Director | 2022-08-04 | Oct 1975 | British |
| JEZEK, Jan, Dr | Director | 2024-07-17 | Nov 1971 | Czech |
Show 7 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| CHOUDHARY, Shafiq Mohammed, Dr | Director | 2021-01-08 | 2023-09-22 |
| DAY LOWTHER, Susan | Director | 2022-08-04 | 2024-07-17 |
| GALLOWAY, John Leslie | Director | 2020-04-06 | 2022-08-04 |
| HIGGINS, Stephen John | Director | 2021-04-01 | 2021-09-14 |
| KENNEDY, Madeleine Elizabeth | Director | 2021-09-14 | 2022-08-04 |
| RICHINGS BARROW, Wendy | Director | 2021-04-01 | 2022-01-20 |
| KRUK PVT LTD | Corporate Director | 2020-04-06 | 2020-08-24 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Arecor Therapeutics Plc | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2022-08-04 | Active |
Filing timeline
Last 20 of 57 total filings
Material constitutional events — rename, articles re-file, resolution
- 2022-09-01 RESOLUTIONS Resolution
- 2022-08-22 MA Memorandum articles
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-06-20 | AA | accounts | Accounts with accounts type full | |
| 2026-04-29 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-11-03 | AD01 | address | Change registered office address company with date old address new address | |
| 2025-10-30 | AD01 | address | Change registered office address company with date old address new address | |
| 2025-06-19 | AA | accounts | Accounts with accounts type full | |
| 2025-05-09 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-03-24 | AP01 | officers | Appoint person director company with name date | |
| 2024-09-11 | AA | accounts | Accounts with accounts type full | |
| 2024-07-18 | AP01 | officers | Appoint person director company with name date | |
| 2024-07-18 | TM01 | officers | Termination director company with name termination date | |
| 2024-04-29 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2023-10-04 | TM01 | officers | Termination director company with name termination date | |
| 2023-07-17 | AA | accounts | Accounts with accounts type full | |
| 2023-05-23 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2022-12-15 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2022-11-15 | AA01 | accounts | Change account reference date company current shortened | |
| 2022-11-01 | AA | accounts | Accounts with accounts type total exemption full | |
| 2022-09-01 | SH01 | capital | Capital allotment shares | |
| 2022-09-01 | RESOLUTIONS | resolution | Resolution | |
| 2022-08-22 | MA | incorporation | Memorandum articles |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 4
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.